👋 Hey, let’s get into it. Samsung already makes your phone, your TV, your refrigerator, your washing machine, and probably the appliance that's currently beeping somewhere in your house for no apparent reason.

Now the South Korean giant wants to make the peptides behind some of biotech's hottest medicines too.

Samsung Biologics is spending $1.8 billion to acquire PolyPeptide Group, giving the company a major foothold in one of the fastest-growing corners of pharma. As GLP-1 demand continues reshaping the industry, even consumer electronics giants are finding reasons to chase obesity drugs. At this rate, don't be surprised if the next Samsung commercial features refrigerators on one side of the screen and GLP-1s on the other.

🍄 Lilly Spends Up to $3.8B to Challenge J&J in Psychedelic Depression Market
Eli Lilly is continuing its acquisition streak with a $2.8 billion upfront purchase of AtaiBeckley, plus milestone payments that could push the deal to roughly $3.8 billion. The prize is BPL-003, an intranasal 5-MeO-DMT therapy that produced rapid improvements in treatment-resistant depression during Phase 2b testing. Unlike Johnson & Johnson's Spravato, many patients receiving BPL-003 were ready for discharge after just 90 minutes, potentially making treatment more convenient. Lilly is betting psychedelic therapies are becoming a legitimate new frontier in mental health.

🤖 BMS and NVIDIA Build Life Sciences' Most Powerful AI Supercomputer
Bristol Myers Squibb is doubling down on artificial intelligence with NVIDIA, expanding its infrastructure to build what the company calls the most powerful AI factory in life sciences. Powered by NVIDIA's latest DGX SuperPOD systems, the platform is designed to help researchers spend less time on repetitive tasks and more time making scientific decisions. The investment builds on BMS' growing AI ecosystem, which already includes collaborations with Anthropic and Microsoft, underscoring how pharmaceutical companies increasingly view AI as standard research infrastructure rather than an experimental technology.

💊 Merck Wins FDA Approval for the World's First Oral PCSK9 Cholesterol Drug
Merck scored a major regulatory victory after the FDA approved Lipfendra (enlicitide), the world's first oral PCSK9 inhibitor for adults with hypercholesterolemia. Unlike existing injectable PCSK9 therapies, Lipfendra offers patients a once-daily pill that can be stored at room temperature. Analysts believe the medicine could eventually generate around $5 billion in annual sales, giving Merck another potential blockbuster as it prepares for the eventual patent expiration of cancer powerhouse Keytruda. Investors welcomed the approval, sending Merck shares higher following the announcement.

🫁 GSK Abandons $2B Cough Drug Bet After Mixed Phase 3 Results
GSK has ended development of camlipixant after mixed Phase 3 results extinguished hopes for one of the company’s most closely watched pipeline assets. The high dose significantly reduced 24-hour cough frequency at Week 12 in the CALM-1 trial, but the drug missed other endpoints and failed the primary endpoint at Week 24 in CALM-2. GSK acquired camlipixant through its $2 billion purchase of Bellus Health in 2023. The company concluded the treatment was unlikely to transform patient care…a very expensive way to clear your throat.

🧬 Jennifer Doudna Uses AI to Design Never-Before-Seen Gene-Editing Enzymes
CRISPR pioneer Jennifer Doudna is entering AI-powered protein design with a platform capable of creating entirely new gene-editing enzymes. Her team designed artificial versions of TnpB, a tiny evolutionary ancestor of CRISPR-Cas, that successfully cut DNA in human, plant, and bacterial cells. Their small size could make the editors easier to package and deliver into specific organs. Beyond medicine and agriculture, the approach could also generate enzymes different enough to navigate existing patents.

😊 Start therapy today, feel better tomorrow
Get matched with a licensed therapist and get flexible support by chat, phone, or video. Take control of your mental health today and save 20% on your first month.
*Offer valid for new users only, cannot be combined with insurance

🦟 India Approves Takeda's Dengue Vaccine
Takeda's QDENGA became the first dengue vaccine approved in India, where mosquito-borne infections remain a major public health challenge.

✅ Novartis Secures Full FDA Approval for Fabhalta
The FDA converted Fabhalta's accelerated approval into a traditional approval, strengthening Novartis' growing dominance in the IgA nephropathy treatment market.

🏛️ Senators Push Drug Supply Chain Transparency Bill
A bipartisan Senate proposal would require the U.S. government to map foreign investment and manufacturing across pharmaceutical supply chains.

📈 Scribe Targets $96M IPO to Fund Gene Silencing Meds
Jennifer Doudna-backed Scribe Therapeutics plans to raise $96 million to advance its gene-silencing cardiovascular medicines into clinical development.

💵 Dimerix Buys Phase 2 Kidney Disease Drug
Dimerix paid $5 million upfront for Mission Therapeutics' acute kidney injury program in a deal worth up to $292 million.

🤩 Takeda's Psoriasis Pill Impresses Again
New Phase 3 data showed Takeda's once-daily zasocitinib cleared or nearly cleared scalp psoriasis in roughly 75% of treated patients.

Sports? Sure. Elections? Apparently. The weather? Somehow, yes. Clinical trials? Welcome to biotech in 2026.

Prediction market platform Kalshi has launched a pilot program allowing users to wager on the outcomes of late-stage clinical trials and FDA regulatory decisions. Built in partnership with AppliedXL, the contracts are tied to objective public documents such as ClinicalTrials.gov endpoints, FDA approval letters, and advisory committee votes. Instead of betting on whether an entire biotech company succeeds, traders can now place bets on the fate of individual drug programs.

Kalshi argues the markets simply turn scattered public information into a transparent probability that anyone can see. Rather than relying on Wall Street analysts or biotech Twitter, the collective wisdom of scientists, physicians, investors, and industry observers could theoretically produce better forecasts for whether a drug will succeed. It's essentially Wall Street's prediction markets applied to medicine.

Not everyone is buying the idea. Bioethicists, physicians, and clinical trial experts have warned that attaching financial incentives to drug development creates a host of uncomfortable questions. Could investigators, company employees, or healthcare workers with nonpublic information attempt to profit from insider knowledge? Could betting markets create incentives to delay or influence trial decisions? Even if regulators catch misconduct later, the integrity of the trial itself may already be compromised.

Reddit's biotech community was equally divided. Some argued this isn't fundamentally different from buying shares of a small biotech whose valuation depends almost entirely on a single clinical readout. Others worried prediction markets create even stranger incentives, including the possibility of people rooting for a trial to fail because that's the profitable outcome. A few commenters even questioned whether patients might hesitate to enroll in a study if they saw thousands of traders betting against its success.

Biotech has always been full of calculated risks. The question now is whether those risks belong in a laboratory…or on a betting slip.

That's how much pharmaceutical and medical device companies paid physicians and teaching hospitals in 2025 through the federal Open Payments program, a record high. Roughly $9.5 billion supported research, while another $3.9 billion went toward consulting fees, speaking engagements, meals, and other general payments. The American Medical Association notes these relationships don't automatically represent conflicts of interest, but multiple studies have found physicians receiving industry payments are generally more likely to prescribe the sponsoring company's medicines.

Here’s what biotech Redditors are talking about:

📩 Should You Send a Thank-You Email After an Interview?
One Redditor claimed several Big Pharma HR professionals told them thank-you emails don't influence hiring decisions, sparking a surprisingly passionate debate. Most biotech professionals disagreed. The consensus was simple: a short thank-you note probably won't land you the job by itself, but it almost certainly won't hurt. Several hiring managers admitted fewer candidates send them than you'd expect, making the gesture memorable. One commenter even credited an AI-written thank-you email with helping secure an offer after a shaky interview. Fifteen minutes of work for even a tiny advantage? Reddit says send the email.

🤔 Startup Chaos or Big Pharma Chill?
A simple question about workloads turned into a snapshot of today's biopharma job market. Startup employees described barely having time to eat lunch, while one Redditor joked that after their company was acquired by Big Pharma they suddenly worked five-hour days instead of wearing twenty different hats. CRO employees painted the opposite picture, describing chronic understaffing, burnout, and the eternal management promise that hiring is "just one quarter away." Eight quarters later...they're apparently still waiting.

💍 Lilly Invests in Oura's GLP-1 Platform
Eli Lilly invested in wearable maker Oura to expand metabolic health tools for GLP-1 users, building on their recently announced LillyDirect partnership.

🤖 OpenAI Researcher Eyes $2B AI Drug Discovery Startup
OpenAI scientist Miles Wang is reportedly launching an AI drug discovery company that could raise roughly $200 million at a $2 billion valuation.

🧠 China Implants First Commercial Brain-Computer Interface
Chinese company Neuracle successfully implanted its commercial brain-computer interface, allowing a patient with spinal cord injuries to control a robotic glove.

🥬 FDA Says Taylor Farms Cyclospora Finding Was False Alarm
The FDA re-tested lettuce samples linked to a Cyclospora investigation and determined the earlier positive result should be considered a false positive.

🩺 Neko Health Raises $700M to Make Preventive Medicine Feel Like an Annual Software Update
Spotify founder Daniel Ek is betting healthcare should work more like technology. His startup, Neko Health, just raised $700 million to expand its AI-powered preventive screening platform and open its first U.S. clinic. Using proprietary full-body imaging, cardiovascular scans, blood testing, and millions of biometric data points, Neko aims to detect disease long before symptoms appear. The company is reportedly now valued around $7 billion, suggesting investors believe the future of healthcare may involve catching illnesses years before patients ever feel sick.

🐒 July 21, 1925: The Court Said No Monkey Business
On this day in 1925, high school biology teacher John T. Scopes was found guilty of violating Tennessee's Butler Act after teaching Charles Darwin's theory of evolution. The famous Scopes "Monkey Trial" became one of the first courtroom spectacles broadcast to a national audience, pitting legendary defense attorney Clarence Darrow against three-time presidential candidate William Jennings Bryan. Although Scopes was convicted and fined $100, the trial transformed public conversations around science, education, and academic freedom. More than a century later, it’s a reminder that scientific progress has always faced resistance before becoming textbook material.

Thinking back to Samsung...I'm starting to wonder if there's anything the company doesn't make.

Imagine waking up, checking your Samsung phone, grabbing milk from your Samsung refrigerator, turning on your Samsung TV, and then seeing a commercial for Samsung-made peptides before breakfast.

At this rate, BioNucleus may be in the wrong business. Maybe we should pivot into refrigerators before Samsung starts writing biotech newsletters too.

That’s all for today. See you Thursday for the next issue. 👋

✍️ Today’s email was brought to you by Josh Martin.

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead

BioNucleus Briefing lands in the inboxes of 1,300+ scientists, founders, investors, operators, and industry decision-makers twice a week.

If you'd like to sponsor a future issue, just hit reply and let's talk.